Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Zeitschrift für Gastroenterologie

Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

UPUwe PelzerDODo‐Youn OhSQShukui Qin

Discussion

Loading...

Member takes

Overview

Observational findings confirm improved overall survival with durvalumab plus gemcitabine in advanced biliary tract cancer, suggesting significant clinical benefits.

Key Points

  • Durvalumab plus gemcitabine and cisplatin significantly improved overall survival in advanced biliary tract cancer patients.
  • Patients receiving the drug combination observed a meaningful 3-year overall survival benefit.
  • The TOPAZ-1 study utilized tumor and plasma sample analysis to track clinically actionable alterations.
  • Findings highlight the potential for targeted therapies in advanced biliary tract cancer, with evidence from a notable clinical trial.

Cite This Study

Pelzer et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b004https://doi.org/10.1055/s-0045-1810972
View Full Paper
Ask AI
Bookmark
Share